

IN THE CLAIMS:

Please amend the claims as follows:

---

01 15. (Twice amended) A method of identifying a compound that directly decreases Annexin-based multidrug resistance (MDR) in a cell having been rendered MDR by an expression of an Annexin, comprising:

a) incubating said cell with a drug to which said cell is resistant in the presence or absence of a candidate compound; and

b) assessing the effect of said candidate compound on the resistance of said cell to said drug;

wherein a candidate compound is selected, when the resistance of said cell to said drug is measurably lower in the presence of said compound as compared to in the absence thereof.

---

16. The method of claim 15, wherein said cell is a cell having been rendered multidrug resistant (MDR) by an expression of an Annexin nucleic acid molecule.

17. The method of claim 15, wherein said compound is selected from the group consisting of a nucleic acid molecule encoding an Annexin variant, or a part thereof, a dominant negative mutant of an Annexin, a mutant

Annexin, an antibody to Annexin a peptide, and a small molecule.

18. (Amended) The method of claim 17, wherein said candidate compound is an Annexin I antisense nucleic acid.

---

Q2

19. (Twice amended) The method of claim 15, wherein said drug is an anticancer drug.

---

Q3

20. (Amended) A method of directly decreasing Annexin-based MDR in a cell having been rendered MDR by an expression of an Annexin comprising: administering thereto an effective amount of a compound selected from the group consisting of a nucleic acid molecule, a dominant negative mutant of an Annexin, a mutant Annexin protein, an antibody to Annexin, a peptide, and a small molecule, whereby said effective amount of said compound decreases Annexin-based MDR in said cell.

---

21. The method of claim 20, wherein said Annexin-based MDR is Annexin I-based.

D4 22. (Twice amended) The method of claim 21,  
wherein said compound is an Annexin I antisense nucleic  
acid.

23. (Twice amended) The method of claim 21,  
wherein said compound is a calcium chelator or a calcium  
channel blocker.

32. A method of conferring drug resistance to a  
cell, comprising an increase in the expression of an  
Annexin protein, whereby said increased expression is  
capable of conferring MDR in said cell.

33. The method of claim 32, wherein said Annexin  
protein is Annexin I.

Please cancel claims 34 to 36.

Please add the following new claims.

D5 37. (New) A method of identifying a compound that  
directly increases Annexin-based multidrug resistance  
(MDR) in a cell having been rendered MDR by an expression  
of an Annexin, comprising:

a) incubating said cell with a drug to which said cell is resistant in the presence or absence of a candidate compound; and

b) assessing the effect of said candidate compound on the resistance of said cell to said drug;

wherein a candidate compound is selected, when the resistance of said cell to said drug is measurably higher in the presence of said compound as compared to in the absence thereof.

DS  
Conf

38. (New) The method of claim 37, wherein said cell is a cell having been rendered multidrug resistant (MDR) by an expression of an Annexin nucleic acid molecule.

39. (New) A method of directly increasing Annexin-based MDR in a cell having been rendered MDR by an expression of an Annexin comprising: administering thereto an effective amount of a compound selected from the group consisting of a nucleic acid molecule, a dominant positive mutant of an Annexin, a mutant Annexin protein and a peptide, and a small molecule whereby said effective amount of said compound increases Annexin-based MDR in said cell.